Clinical Trials
6 trialsNCT04720716 2026-03-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT04297280 2025-02-27
TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma
Fudan University
Phase 2 Completed
NCT04954794 2024-10-31
TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)
Fudan University
Phase 2 Completed
NCT04842565 2024-05-22
cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria
Fudan University
Phase 2 Completed
NCT04618367 2024-03-06
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
Sun Yat-sen University
Phase NA Completed
NCT04627012 2024-03-06
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Completed